Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324944 | 0.85 | NPSR1 (0.46) | NPSR1KMT2AMEN1HIF1A | |
| SCHEMBL4330748 | 0.80 | KDM4E (0.62) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL13097974 | 0.78 | NPSR1 (0.64) | NPSR1KMT2AMEN1HIF1AHCRTR1 | |
| SCHEMBL3208935 | 0.75 | HCRTR1 (0.80) | NPSR1KMT2AMEN1HIF1AHCRTR1 | |
| SCHEMBL9951667 | 0.75 | NPSR1 (0.67) | NPSR1KMT2AMEN1HIF1AALDH1A1 | |
| SCHEMBL3199672 | 0.75 | NPSR1 (0.67) | NPSR1KMT2AMEN1HIF1AALDH1A1 | |
| SCHEMBL4336004 | 0.74 | ALDH1A1 (0.48) | NPSR1KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL1952758 | 0.72 | SCN5A (0.58) | HIF1AHPGD | |
| SCHEMBL18196460 | 0.72 | MAPK1 (0.60) | NPSR1KMT2AMEN1HIF1AHCRTR1 | |
| SCHEMBL2928283 | 0.71 | SCN5A (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-20090312424-A1 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-12-17 | — | — | US | claimed |
| US-7576127-B2 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11628178-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | disclosed |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-08-25 | — | — | US | disclosed |
| WO-2022169520-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-20090312424-A1 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7230003-B2 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050107385-A1 | Aromatic prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312424-A1 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | CYP2C19, CYP3A5, CYP2C9 | NPSR1 1412/4885KMT2A 1110/4885MEN1 1171/4885 |
| US-20050107385-A1 | Aromatic prodrugs of propofol, compositions and uses thereof | CYP2C19, CYP3A5, CYP2C9 | NPSR1 1412/4885KMT2A 1110/4885MEN1 1171/4885 |
| US-11628178-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | NPSR1 500/4885KMT2A 3254/4885MEN1 797/4885 |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | NPSR1 500/4885KMT2A 3254/4885MEN1 797/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | NPSR1 500/4885KMT2A 3254/4885MEN1 797/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | NPSR1 500/4885KMT2A 3254/4885MEN1 797/4885 |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | NPSR1 500/4885KMT2A 3254/4885MEN1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.